Le Lézard
Classified in: Health
Subjects: LAW, SVY, POL, CFG, MAT

Health Canada Launches Public Consultations on Proposed Approach to Cost Recovery for the Regulation of Cannabis


OTTAWA, July 12, 2018 /CNW/ - The Cannabis Act has been passed by Parliament and will come into force on October 17, 2018.

Last year, the Government of Canada committed to providing the necessary resources to implement the Cannabis Act. At the same time, the Government committed to fully recovering the costs of regulating the new cannabis industry. Cost recovery will ensure that those who benefit from the new legal market will pay the costs of regulating cannabis, which will reduce the cost to Canadians.

Today, Health Canada is launching a 30-day public consultation on the proposed approach to cost recovery for the regulation of cannabis. The proposed cost-recovery approach is guided by the principles that fees should allow for both larger and smaller players in a diverse market. The approach proposes to collect no more than the cost of delivering the regulatory program.

The cost-recovery proposal includes four fees:

To promote a diverse market, Health Canada proposes to scale fees according to the size of the business and to provide for lower fees for the newly proposed micro-scale licence holders. Some classes of licences?namely those for research, analytical testing and hemp production?would be exempt from fees. To maintain access to cannabis for medical purposes, those who produce, cultivate and sell cannabis exclusively for medical purposes would be exempt from the annual regulatory fee.

The proposed approach to cost recovery is outlined in the consultation paper Proposed Approach to Cost Recovery for the Regulation of Cannabis.

All Canadians and interested stakeholders are invited to share their views on the proposed regulatory approach online until August 13, 2018. Health Canada welcomes written submissions or input provided online.

Quotes

"Cost recovery is a standard practice across the Government of Canada to support program delivery. The proposed fees have been designed to enable a diverse and competitive legal industry made up of large and small players, to facilitate research and development, and to maintain access to cannabis for medical purposes. We look forward to hearing the views of Canadians on our proposed approach."
The Honourable Ginette Petitpas Taylor
Minister of Health

"The previous approach to cannabis was not working. Our goal in legalizing and strictly regulating cannabis is to keep it out of the hands of youth and profits out of the pockets of criminals and organized crime. We also aim to minimize the cost to Canadians of regulating the cannabis industry. Implementing cost recovery will do just that. I encourage all interested Canadians to share their views with us."
Bill Blair
Parliamentary Secretary to the Minister of Justice and Attorney General of Canada and to the Minister of Health

Quick Facts

Associated Links
Consultation Paper ? Proposed Approach to Cost Recovery for the Regulation of Cannabis 
Participate in the Consultation 
Canada.ca/Cannabis

 

SOURCE Health Canada


These press releases may also interest you

at 06:03
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...

at 06:00
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...

at 05:30
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...

at 05:09
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period. The...

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...



News published on and distributed by: